Biorefic
The business, the turning points, and the decisions behind them.
Some sections are still being researched1 / 4
Sections to complete：03
01 / WHAT IT BUILT
What the company did
Biorefic was a Ventspils, Latvia-based biorefinery startup founded in 2021 by co-founder Emils Paupe-Balodis. It developed a next-generation zero-waste biorefinery technology upcycling agricultural residues into advanced prebiotic ingredients - xylooligosaccharide prebiotics for gut-microbiome health - plus microbial/algal Omega-3 fatty acids and alternative lipids and proteins for animal feed and aquaculture, without using food inputs. It aimed to offset 10 million tons of CO2e by 2030 through more efficient livestock farming, joined the RootCamp accelerator's third batch, and raised about $350,000 ($300K seed in May 2021). PitchBook now lists it as 'Out of Business'.
02 / Biorefic FAILURE REASONS
Failure reasons
No founder post-mortem is public; PitchBook lists the company as out of business after raising only about $350,000. The pattern is the biotech capex trap: a biorefinery startup selling prebiotic ingredients must prove its product through animal trials, scale its process, and build a plant before meaningful revenue - with two employees and $350K, that is effectively impossible. The business was backward-integrated into agricultural supply chains, which means long adoption cycles and deep dependence on partners' balance sheets. When the grant and seed money ran out, there was no capital to build the plant, and the related venture - the renewable methanol project - continued under a separate entity (Biorefic NRG), not the original company.
03 / EVENT HISTORY
Material for this section is being gathered and checked. It will appear here once ready.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Biotech ingredients need real capital: $350K buys research, not a plant - match your ambition to your balance sheet.
- 02
Prove unit economics before building: prebiotics must win trials, then shelf space, then scale - each step needs its own funding.
- 03
Backward-integrated businesses inherit their partners' timelines: agricultural supply chains move in seasons, not sprints.
- 04
Two people cannot industrialise a process: scale chemistry is a team sport with real payroll.
- 05
When the plant never gets built, the IP dies quietly: no announcement, just an 'Out of Business' flag.